NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

It's not that important really for the trial.
The likelihood is that 95% of trial subjects are wildtype.
And the 5% with IDH mutation are way too small a group to draw any meaningful conclusions.

They said as much two years ago in JTM:-

The mutation status of the IDH1 gene has not yet been investigated for this trial, as this factor was not included in trial designs a decade ago when this trial began. It will be collected and analyzed later, but is unlikely to explain the overall survival results, as the mutation associated with prolonged survival occurs in less than 10% of newly diagnosed glioblastoma patients

But I imagine they were asked to collate this in a regulator SAP response. I don't even know how they can do it technically, unless they have remaining tumor tissue for all patients.

(Of course it is important to a patient's prognosis. If you're a patient with a secondary glioblastoma and IDH mutations, you're going to be 20yrs younger on average and have perhaps twice the life expectation.)